0001193125-26-098531
SEC filingMyomo, Inc. reported revenue of $40.9 million for fiscal year 2025, generating a gross profit of $26.9 million. However, the company incurred significant operating expenses totaling $41.3 million, resulting in an operating loss of $14.4 million. After accounting for other expenses and income tax expense of $505,000, the net loss was $15.6 million. The company's cash position declined by $10.0 million during the year, ending with $14.1 million in cash and cash equivalents. Financing activities provided $11.4 million in cash, primarily from debt issuances including $12.5 million from Avenue Capital, while operating activities used $14.5 million in cash. The balance sheet shows total assets of $38.6 million, total liabilities of $27.2 million, and stockholders' equity of $11.4 million, with accumulated deficit reaching $118.7 million.
Myomo, Inc. reported revenue of $40.9 million for fiscal year 2025, with cost of revenue totaling $14.0 million, resulting in gross profit of $26.9 million. Operating expenses were substantial at $41.3 million, comprising research and development ($6.9 million), selling, clinical, and marketing ($20.4 million), and general and administrative expenses ($14.0 million). This led to an operating loss of $14.4 million. Other expenses totaled $668,000, and after income tax expense of $505,000, the company reported a net loss of $15.6 million. The company's cash position declined by $10.0 million during the year, ending with $14.1 million in cash and cash equivalents.
The filing does not provide segment breakdown or geographic mix data for revenue. Revenue of $40.9 million represents the total product and service revenue for the period. No specific growth drivers or product line details are disclosed in the provided financial data. The company's revenue generation appears to be consolidated without segment-level disclosure in the available information.
The company achieved a gross margin of 65.8% ($26.9 million gross profit on $40.9 million revenue). However, operating expenses consumed 101% of revenue, resulting in negative operating margin of -35.2%. The cost structure shows selling, clinical, and marketing expenses represented 49.9% of revenue, while research and development accounted for 16.9% and general and administrative expenses represented 34.2% of revenue. The net loss margin was -38.1%.
Operating activities used $14.5 million in cash, primarily due to the net loss of $15.6 million, partially offset by non-cash adjustments including $2.1 million in stock-based compensation. Investing activities used $7.1 million for equipment purchases ($1.7 million), software development ($1.6 million), and net purchases of short-term investments. Financing activities provided $11.4 million, mainly from debt issuances including $12.5 million from Avenue Capital, offset by $4.0 million in debt repayments. The balance sheet shows total assets of $38.6 million, with current assets of $27.6 million including cash ($14.1 million), short-term investments ($4.3 million), and accounts receivable ($4.1 million). Total liabilities stand at $27.2 million, including long-term debt of $11.2 million and operating lease liabilities of $8.2 million.
The filing does not provide management guidance, strategic priorities, or specific forward-looking statements in the provided financial data. No risk factors or future projections are included in the extracted financial statements. The company's financial position shows continued losses and cash consumption, with financing activities providing necessary liquidity through debt issuances during the period.